Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMENICA: Dostarlimab vs Chemotherapy in MMR Deficient Endometrial Cancer
NCT05201547Phase 3Active, not recruiting
- Sponsor
- ARCAGY
- Start
- Apr 2022
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 10
01
Overview
A Phase 3 trial of dostarlimab in endometrial cancer (EC), sponsored by ARCAGY. Started Apr 2022; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05201547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201547.